What is the average price target for NUTRIEN LTD (NTR) stock?
27 analysts have analysed NTR and the average price target is 56.78 USD. This implies a price decrease of -19.6% is expected in the next year compared to the current price of 70.62.
NYSE:NTR • CA67077M1086
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUTRIEN LTD (NTR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-08 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-26 | UBS | Downgrade | Neutral -> Sell |
| 2026-03-18 | BMO Capital | Maintains | Outperform -> Outperform |
| 2026-03-18 | B of A Securities | Maintains | Neutral -> Neutral |
| 2026-03-17 | CIBC | Maintains | Outperformer -> Outperformer |
| 2026-03-13 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2026-03-12 | Jefferies | Upgrade | Hold -> Buy |
| 2026-03-03 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-23 | Jefferies | Maintains | Hold -> Hold |
| 2026-02-20 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-20 | B of A Securities | Maintains | Neutral -> Neutral |
| 2026-02-18 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-02 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2026-01-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-16 | Mizuho | Maintains | Neutral -> Neutral |
| 2026-01-14 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2026-01-12 | UBS | Maintains | Neutral -> Neutral |
| 2025-12-18 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-11-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-10 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-11-06 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-11-06 | UBS | Maintains | Neutral -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 29.056B -23.30% | 25.972B -10.61% | 26.885B 3.52% | 26.994B 0.41% | 26.694B -1.11% | 26.731B 0.14% | 28.149B 5.30% | 28.634B 1.72% | 29.715B 3.78% | 30.356B 2.16% | 31.01B 2.15% | |
| EBITDA YoY % growth | 5.971B -49.65% | 5.288B -11.44% | 5.954B 12.59% | 6.618B 11.15% | 6.233B -5.82% | 6.178B -0.88% | 6.061B -1.89% | 6.254B 3.18% | 6.448B 3.10% | 6.55B 1.58% | 6.652B 1.56% | |
| EBIT YoY % growth | 3.802B -61.39% | 2.949B -22.44% | 3.585B 21.57% | 4.355B 21.48% | 3.922B -9.94% | 3.713B -5.33% | 3.51B -5.47% | 3.978B 13.33% | 3.866B -2.82% | 3.93B 1.66% | 3.995B 1.65% | |
| Operating Margin | 13.09% | 11.35% | 13.33% | 16.13% | 14.69% | 13.89% | 12.47% | 13.89% | 13.01% | 12.95% | 12.88% | |
| EPS YoY % growth | 4.36 -66.67% | 3.50 -19.72% | 4.56 30.29% | 5.62 23.29% | 5.07 -9.89% | 5.04 -0.50% | 5.07 0.52% | 4.95 -2.23% | 4.96 0.10% | 5.05 1.83% | 5.15 2.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.53 383.36% | 2.76 4.27% | 0.93 -3.97% | 0.86 3.25% | 0.56 4.86% | 2.81 1.55% | 0.87 -6.11% | 0.87 1.36% |
| Revenue Q2Q % growth | 5.309B 8.92% | 10.249B 0.50% | 5.539B -3.42% | 5.162B 0.39% | 5.372B 1.19% | 10.628B 3.70% | 5.784B 4.42% | 5.309B 2.85% |
| EBITDA Q2Q % growth | 1.092B 33.17% | 2.511B -16.99% | 1.351B -47.92% | 1.248B -59.39% | 1.079B -1.19% | 2.454B -2.27% | 1.346B -0.37% | 1.254B 0.48% |
| EBIT Q2Q % growth | 505.69M 103.09% | 1.885B 2.45% | 655.89M -17.19% | 674.94M -4.13% | N/A | N/A | N/A | N/A |
All data in USD
27 analysts have analysed NTR and the average price target is 56.78 USD. This implies a price decrease of -19.6% is expected in the next year compared to the current price of 70.62.
NUTRIEN LTD (NTR) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of NUTRIEN LTD (NTR) is 0.53 USD and the consensus revenue estimate is 5.31B USD.
The consensus rating for NUTRIEN LTD (NTR) is 74.8148 / 100 . This indicates that analysts generally have a positive outlook on the stock.